SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
The four types of dementia most people don’t know exist 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Daiichi Sankyo shares tumbled sharply on Friday after the Japanese pharmaceutical company announced a delay in its annual earnings release, raising concerns among investors about its oncology business and potential financial losses. The stock of Daiichi Sankyo Co., Ltd. (TYO:4568) fell nearly 10% to 2,505.5 yen, marking its lowest level since March 2022 and making it one of the worst-performing stocks in the Nikkei 225, despite the index edging up 0.3%.
The company confirmed that it has postponed its earnings announcement to May 11 from the originally scheduled date of April 27. This decision comes as Daiichi Sankyo conducts a detailed review of its oncology portfolio, including supply chain plans and its drug development pipeline. According to the company, rapidly changing market conditions have made it necessary to reassess its projections, particularly regarding potential loss provisions linked to contract manufacturers.
In addition to the earnings delay, Daiichi Sankyo also rescheduled the release of its five-year business plan to May 11, moving it forward from the previously planned May 19 date. This shift highlights the company’s effort to provide a more comprehensive update alongside its financial results.
The delay occurs during a period of strategic transformation for Daiichi Sankyo. Earlier in April, the company sold its over-the-counter drug unit, Daiichi Sankyo Healthcare, to Suntory Holdings. This move aligns with its long-term strategy to concentrate on its core prescription drug business and strengthen its oncology pipeline.
Daiichi Sankyo has been heavily investing in cancer treatments, with a strong focus on innovative therapies like Enhertu, a high-profile drug co-developed with AstraZeneca. While this focus positions the company for future growth in the oncology market, the current uncertainty surrounding supply planning and financial adjustments has weighed on investor sentiment.
As Daiichi Sankyo navigates these challenges, market participants will closely watch its upcoming earnings report and strategic updates for clearer insights into its financial outlook and growth trajectory.
